136 related articles for article (PubMed ID: 32015192)
1. Novel psychoactive substances (NPS) - knowledge and expe riences of drug users from Hungary, Poland, the UK and the USA.
Pisarska A; Deluca P; Demetrovics Z; Moskalewicz J; ReDNet G
Neuropsychopharmacol Hung; 2019 Dec; 21(4):152-163. PubMed ID: 32015192
[TBL] [Abstract][Full Text] [Related]
2. Motives for using new psychoactive substances in three groups of Polish users: nightlife, marginalised and active on the In.
Wieczorek Ł; Dąbrowska K; Bujalski M
Psychiatr Pol; 2022 Jun; 56(3):453-470. PubMed ID: 36342979
[TBL] [Abstract][Full Text] [Related]
3. Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project.
Corazza O; Assi S; Simonato P; Corkery J; Bersani FS; Demetrovics Z; Stair J; Fergus S; Pezzolesi C; Pasinetti M; Deluca P; Drummond C; Davey Z; Blaszko U; Moskalewicz J; Mervo B; Furia LD; Farre M; Flesland L; Pisarska A; Shapiro H; Siemann H; Skutle A; Sferrazza E; Torrens M; Sambola F; van der Kreeft P; Scherbaum N; Schifano F
Hum Psychopharmacol; 2013 Jul; 28(4):317-23. PubMed ID: 23881879
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
Gray R; Bressington D; Hughes E; Ivanecka A
J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
[TBL] [Abstract][Full Text] [Related]
5. Awareness of users and motivational factors for using new psychoactive substances in Belgium.
Simonis S; Canfyn M; Van Dijck A; Van Havere T; Deconinck E; Blanckaert P; Gremeaux L
Harm Reduct J; 2020 Jul; 17(1):52. PubMed ID: 32711526
[TBL] [Abstract][Full Text] [Related]
6. Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances.
Deligianni E; Daniel OJ; Corkery JM; Schifano F; Lione LA
Br J Clin Pharmacol; 2020 Mar; 86(3):505-516. PubMed ID: 31495968
[TBL] [Abstract][Full Text] [Related]
7. Veni, vidi, vici: The appearance and dominance of new psychoactive substances among new participants at the largest needle exchange program in Hungary between 2006 and 2014.
Rácz J; Csák R; Tóth KT; Tóth E; Rozmán K; Gyarmathy VA
Drug Alcohol Depend; 2016 Jan; 158():154-8. PubMed ID: 26652897
[TBL] [Abstract][Full Text] [Related]
8. The Growing Problem of New Psychoactive Substances (NPS).
Madras BK
Curr Top Behav Neurosci; 2017; 32():1-18. PubMed ID: 27571747
[TBL] [Abstract][Full Text] [Related]
9. Mapping novel psychoactive substances policy in the EU: The case of Portugal, the Netherlands, Czech Republic, Poland, the United Kingdom and Sweden.
Neicun J; Steenhuizen M; van Kessel R; Yang JC; Negri A; Czabanowska K; Corazza O; Roman-Urrestarazu A
PLoS One; 2019; 14(6):e0218011. PubMed ID: 31242225
[TBL] [Abstract][Full Text] [Related]
10. Lifetime prevalence of novel psychoactive substances use among adults in the USA: Sociodemographic, mental health and illicit drug use correlates. Evidence from a population-based survey 2007-2014.
Neicun J; Yang JC; Shih H; Nadella P; van Kessel R; Negri A; Czabanowska K; Brayne C; Roman-Urrestarazu A
PLoS One; 2020; 15(10):e0241056. PubMed ID: 33125395
[TBL] [Abstract][Full Text] [Related]
11. The diverse reasons for using Novel Psychoactive Substances - A qualitative study of the users' own perspectives.
Soussan C; Andersson M; Kjellgren A
Int J Drug Policy; 2018 Feb; 52():71-78. PubMed ID: 29241144
[TBL] [Abstract][Full Text] [Related]
12. Drugs of Abuse and Novel Psychoactive Substances at Outdoor Music Festivals in Colorado.
Fox J; Smith A; Yale A; Chow C; Alaswad E; Cushing T; Monte AA
Subst Use Misuse; 2018 Jun; 53(7):1203-1211. PubMed ID: 29148866
[TBL] [Abstract][Full Text] [Related]
13. A market on both "sides" of the law: The use of the hidden web for the sale of new psychoactive substances.
Wadsworth E; Drummond C; Kimergård A; Deluca P
Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28617997
[TBL] [Abstract][Full Text] [Related]
14. New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries.
Kurcevič E; Lines R
Harm Reduct J; 2020 Nov; 17(1):94. PubMed ID: 33256747
[TBL] [Abstract][Full Text] [Related]
15. New psychoactive substance use as a survival strategy in rural marginalised communities in Hungary.
Csák R; Szécsi J; Kassai S; Márványkövi F; Rácz J
Int J Drug Policy; 2020 Nov; 85():102639. PubMed ID: 31911024
[TBL] [Abstract][Full Text] [Related]
16. The role of illicit, licit, and designer drugs in the traffic in Hungary.
Institóris L; Hidvégi E; Dobos A; Sija É; Kereszty ÉM; Tajti LB; Somogyi GP; Varga T
Forensic Sci Int; 2017 Jun; 275():234-241. PubMed ID: 28412575
[TBL] [Abstract][Full Text] [Related]
17. The Scale of Intoxications with New Psychoactive Substances over the Period 2014-2020-Characteristics of the Trends and Impacts of the COVID-19 Pandemic on the Example of Łódź Province, Poland.
Garus-Pakowska A; Kolmaga A; Gaszyńska E; Ulrichs M
Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457295
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of psychiatric inpatients diagnosed with mental and behavioral disorders caused by psychoactive substances (F11-19 block), with a focus on NPS and psychiatric co-morbidities.
Engelgardt P; Krzyżanowski M; Piotrowski P; Borkowska-Sztachańska M; Wasilewska A; Kowalkowski T
Int J Occup Med Environ Health; 2020 Mar; 33(2):125-136. PubMed ID: 31942874
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of new psychoactive substances (NPS) in Brazil based on oral fluid analysis of samples collected at electronic music festivals and parties.
da Cunha KF; Oliveira KD; Cardoso MS; Arantes ACF; Coser PHP; Lima LN; Maluf ACS; Comis MAC; Huestis MA; Costa JL
Drug Alcohol Depend; 2021 Oct; 227():108962. PubMed ID: 34461412
[TBL] [Abstract][Full Text] [Related]
20. Why do people use new psychoactive substances? Development of a new measurement tool in six European countries.
Benschop A; Urbán R; Kapitány-Fövény M; Van Hout MC; Dąbrowska K; Felvinczi K; Hearne E; Henriques S; Kaló Z; Kamphausen G; Silva JP; Wieczorek Ł; Werse B; Bujalski M; Korf D; Demetrovics Z
J Psychopharmacol; 2020 Jun; 34(6):600-611. PubMed ID: 32043399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
